 Pliant Therapeutics

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Enrollment complete in INTERGRIS-IPF Phase 2a clinical trial with top-line data expected mid-2022

Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 40th Annual J.P Morgan Healthcare Conference. The virtual presentation will begin on Wednesday, January 12, 2022, at 9:45 a.m. ET /6:45 a.m. PT.

Pliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Pliant Therapeutics, Inc. (PLRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Pliant Therapeutics, Inc. (PLRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (“the Company”), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2021 financial results.

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, will participate in a virtual fireside chat as part of the Piper Sandler Lung Day on Friday, October 15, 2021, at 11:00 a.m. ET.

Pliant Therapeutics to Participate in Piper Sandler Lung Day

A positive phase 2 clinical trial readout was a positive step in the right direction for this biotech start-up.

Why Pliant Therapeutics Stock Is Surging Today

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue a pre-market press release and conduct a conference call and webcast on Tuesday, September 7, 2021, to discuss interim clinical data from an ongoing Phase 2a positron emission tomography (PET) imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF).

Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

- PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 RBC Capital Markets Global Healthcare Conference to be held virtually from May 18 –19, 2021.

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 20th Annual Needham Healthcare Conference to be held virtually from April 12 –15, 2021.

Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference

- PLN-74809 Phase 2a PET Imaging Trial Resumed, with Preliminary Data Expected First Half of 2021

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the successful completion of a Phase 1 trial of PLN-1474, an oral, small-molecule selective inhibitor of the integrin αvβ1 in development for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis. Following the successful completion of this study, PLN-1474 has been transferred to Novartis.

Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. David Pyott, former Chairman and Chief Executive Officer of Allergan, to Pliant's Board of Directors.

Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors

PLRX has a pipeline targeting various fibrotic diseases. It has in-licensed technology from the UCSF, and collaborations with Novartis.

Pliant Therapeutics: An Early Stage Company With Important Collaborations

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported...

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced a poster presentation at The Liver Meeting®...

Pliant Therapeutics to Present Data at The Liver Meeting® 2020

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

Pliant Therapeutics To Participate In Upcoming Virtual Investor Conferences

SAN FRANCISCO, Aug. 27, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

Pliant Therapeutics Presents Data at The Digital International Liver Congress™ 2020

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc.

Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results

There's a chance that it could become an even bigger success story.

Could This Recent IPO Biotech Become the Next Moderna?

SOUTH SAN FRANCISCO, Calif., June 5, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the closing of its initial public offering of...

Pliant Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

Pliant Therapeutics Inc. (NASDAQ:PLRX) has knocked it out of the park since joining the ranks of public companies on Wednesday.

Pliant Therapeutics Shares Have Climbed 44% Since This Week’s IPO

Investors are excited about the biotech's prospects, but the company still has a long road ahead.

Pliant Therapeutics Up 33% on IPO Pricing

Pliant Therapeutics Inc. shares PLRX, +56.25% soared 55% in their trading debut Wednesday, after the company's initial public offering priced at $16 a share, the high end of its $14 to $16 range.

News for Pliant Therapeutics Stock (PLRX)